Under the agreement with Chimerix, Merck will be responsible for development and commercialization of CMX157, an investigational oral nucleoside reverse transcriptase inhibitor currently in Phase I clinical development. EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) is a novel nucleoside...
FULL ARTICLE AT Pharmaceutical Industry News